Expert review puts GLP-1 gastrointestinal side effects at 30% to 50% of patients

The wire

1. 01The narrative review in Nutrition in Clinical Practice synthesizes trials, observational data and pharmacovigilance on nausea, vomiting, diarrhea and constipation, most common during initiation and dose escalation.
2. 02Authors say peri-procedural data show increased residual gastric volume without confirmed aspiration events, and that most events are manageable with titration and dietary change.
3. 03Early data on retatrutide, survodutide and cagrilintide-semaglutide suggest a similar profile, but the authors call that evidence largely limited; this is a narrative review, not a systematic one.

From the source

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 Oct · Singhani V, Ehsan M, Valencia S et al.